WO2011146819A3 - METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES - Google Patents
METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES Download PDFInfo
- Publication number
- WO2011146819A3 WO2011146819A3 PCT/US2011/037308 US2011037308W WO2011146819A3 WO 2011146819 A3 WO2011146819 A3 WO 2011146819A3 US 2011037308 W US2011037308 W US 2011037308W WO 2011146819 A3 WO2011146819 A3 WO 2011146819A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- integrin
- treatment
- methods
- mediated
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention features compositions, methods, and kits useful for the treatment of diseases mediated by NF-κΒ and diseases suppressed by α7 integrin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL223095A IL223095A0 (en) | 2010-05-20 | 2012-11-18 | Methods and compositions for treatment nf-kb-mediated and a7 integrin-suppressed diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34674010P | 2010-05-20 | 2010-05-20 | |
US61/346,740 | 2010-05-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011146819A2 WO2011146819A2 (en) | 2011-11-24 |
WO2011146819A3 true WO2011146819A3 (en) | 2012-05-10 |
Family
ID=44992357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/037308 WO2011146819A2 (en) | 2010-05-20 | 2011-05-20 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES |
Country Status (2)
Country | Link |
---|---|
IL (1) | IL223095A0 (en) |
WO (1) | WO2011146819A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105560233B (en) * | 2015-12-25 | 2018-11-20 | 东北制药集团沈阳第一制药有限公司 | A kind of medical composition and its use of jamaicin and fenofibrate |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140330022A1 (en) * | 2012-01-05 | 2014-11-06 | Kowa Company, Ltd. | Collateral blood circulation development promoter |
ITRM20120550A1 (en) * | 2012-11-09 | 2014-05-10 | Ist Fisioterap Ospitalroma | INTEGRINE INHIBITOR FOR TREATMENT OR PREVENTION OF CANCER. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003019144A2 (en) * | 2001-08-27 | 2003-03-06 | Biswas Debajit K | METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE |
US20070270455A1 (en) * | 2005-07-20 | 2007-11-22 | Gudkov Andrei V | INHIBITION OF NF-kB |
US20080187595A1 (en) * | 2005-08-19 | 2008-08-07 | Andreas Jordan | Method For Carrying Therapeutic Substances Into Cells |
US20090004658A1 (en) * | 2007-04-30 | 2009-01-01 | Jianhua Luo | Integrin alpha 7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma |
US20100069302A1 (en) * | 2007-07-18 | 2010-03-18 | Stefan Krueger | Specific therapy and medicament using integrin ligands for treating cancer |
-
2011
- 2011-05-20 WO PCT/US2011/037308 patent/WO2011146819A2/en active Application Filing
-
2012
- 2012-11-18 IL IL223095A patent/IL223095A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003019144A2 (en) * | 2001-08-27 | 2003-03-06 | Biswas Debajit K | METHODS AND COMPOSITIONS FOR SCREENING, DIAGNOSING, OR TREATING NF-λB RELATED DISEASE |
US20070270455A1 (en) * | 2005-07-20 | 2007-11-22 | Gudkov Andrei V | INHIBITION OF NF-kB |
US20080187595A1 (en) * | 2005-08-19 | 2008-08-07 | Andreas Jordan | Method For Carrying Therapeutic Substances Into Cells |
US20090004658A1 (en) * | 2007-04-30 | 2009-01-01 | Jianhua Luo | Integrin alpha 7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma |
US20100069302A1 (en) * | 2007-07-18 | 2010-03-18 | Stefan Krueger | Specific therapy and medicament using integrin ligands for treating cancer |
Non-Patent Citations (1)
Title |
---|
G. POCH ET AL.: "Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves", JOURNAL OF PHARMACOLOGICAL METHODS, vol. 4, 1980, pages 179 - 188 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105560233B (en) * | 2015-12-25 | 2018-11-20 | 东北制药集团沈阳第一制药有限公司 | A kind of medical composition and its use of jamaicin and fenofibrate |
Also Published As
Publication number | Publication date |
---|---|
WO2011146819A2 (en) | 2011-11-24 |
IL223095A0 (en) | 2013-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011047146A3 (en) | Methods of affinity maturing antibodies | |
AU2016219704A1 (en) | Anti-Notch1 antibodies | |
WO2014028461A3 (en) | Treatment and diagnosis of melanoma | |
WO2014078268A8 (en) | Anti-hemagglutinin antibodies and methods of use | |
WO2012118903A3 (en) | Sclerostin and dkk-1 bispecific binding agents | |
WO2011133504A3 (en) | Nanozymes, methods of making nanozymes, and methods of using nanozymes | |
WO2011119777A3 (en) | Compositions and methods for treatment of neurodegenerative disease | |
WO2012173846A3 (en) | Peptidomimetic macrocycles | |
WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
WO2013034979A3 (en) | Crystalline forms of cabazitaxel | |
WO2013080217A3 (en) | Crystalline forms of carbazitaxel and process for preparation thereof | |
HK1164304A1 (en) | Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria | |
WO2013164839A3 (en) | Amorphous form of apixaban, process of preparation and compositions thereof | |
WO2012112674A3 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
WO2012129299A3 (en) | Medical instruments and methods for fabricating same | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
WO2013120022A3 (en) | Treatment of hypoglycemia | |
WO2013023151A3 (en) | Compositions and methods for treating celiac sprue disease | |
WO2012037116A3 (en) | Genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof | |
WO2013052108A3 (en) | Methods and compositions for the treatment and diagnosis of ovarian cancer | |
WO2014097318A3 (en) | Agents for eliminating tumour-initiating cells | |
WO2012017321A3 (en) | Treatment for dyslipidemia | |
WO2013155338A8 (en) | Substituted benzamides and their uses | |
WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
WO2012109567A3 (en) | Treatment of angiogenesis disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 223095 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2013511380 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11784309 Country of ref document: EP Kind code of ref document: A2 |